New Brain-Targeting drug tested for schizophrenia relief
NCT ID NCT06442462
Summary
This study is testing whether an investigational drug called SPG302 can help control symptoms and improve daily functioning for adults with schizophrenia. Thirty-two participants will take either SPG302 or a placebo pill daily for six weeks while researchers measure changes in symptoms, brain activity, and quality of life. The goal is to see if SPG302 is safe and effective for managing this complex mental health condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Box Hill Hospital - Eastern Health
Box Hill, Victoria, 3128, Australia
-
CenExel CNS
Garden Grove, California, 92845, United States
-
Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.